Cyclooxygenase-2 and the inflammogenesis of breast cancer

World Journal of Clinical Oncology

Volumn 5, Issue 4, 2014, Pages 677-692

  Harris, Randall E ^a   Casto, Bruce C ^a   Harris, Zachary M ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Aromatase; Breast Cancer; Cyclooxygenase 2; Estrogen; Inflammogenesis; Nonsteroidal anti inflammatory drugs

Indexed keywords

EID: 84920149720     PISSN: None     EISSN: 22184333     Source Type: Journal    
DOI: 10.5306/wjco.v5.i4.677     Document Type: Article

References (176)

1. Virchow R. Reizung and Reizbarkeit. Arch Pathol Anat Klin Med 1858; 14: 1-63
2. Virchow R. Aetiologie der neoplastischen Geschwulst/Pathogenie der neoplastischen Geschwulste. In: Die Krankhaften Geschwulste. Berlin: Verlag von August Hirschwald, 1863: 57-101
3. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545 [PMID: 11229684 DOI: 10.1016/s0140-6736(00)04046-0]
4. Schrieber H, Rowley DA. Inflammation and cancer. In: JI Gallin, R Snyderman, eds. Inflammation: Basic Principles and Clinical Correlates, third ed. Philadelphia: Lippincott Williams & Wilkins, 1999: 1117-1129
5. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867 [PMID: 12490959 DOI: 10.1038/nature01322]
6. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004; 14: 433-439 [PMID: 15489136 DOI: 10.1016/j.semcancer. 2004.06.006]
7. Koki AT, Leahy KM, Harmon JM, Masferrer JL. Cyclooxygenase-2 and cancer. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, Totowa, NJ, 2002: 185-203
8. Jang BC, Hla T. Regulation of expression and potential carcinogenic role of cylcooxygenase-2. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, Totowa, NJ, 2002: 171-184
9. Harris RE. Cyclooxygenase-2 blockade in cancer prevention and therapy: widening the scope of impact. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, Totowa, NJ, 2002: 341-365
10. Harris RE. Cyclooxygenase-2 (cox-2) and the inflammogenesis of cancer. Subcell Biochem 2007; 42: 93-126 [PMID: 17612047]
11. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231: 232-235 [PMID: 5284360 DOI: 10.1038/newbio231232a0]
12. Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992; 89: 7384-7388 [PMID: 1380156 DOI: 10.1073/pnas.89.16.7384]
13. Herschman HR. Regulation of prostaglandin synthase-1 and prostaglandin synthase-2. Cancer Metastasis Rev 1994; 13: 241-256 [PMID: 7712587 DOI: 10.1007/bf00666095]
14. Herschman HR. Historical Aspects of COX-2. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, Totowa, NJ, 2002: 13-32
15. Clària J. Cyclooxygenase-2 biology. Curr Pharm Des 2003; 9: 2177-2190 [PMID: 14529398 DOI: 10.2174/1381612033454054]
16. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb Perspect Biol 2009; 1: a001651 [PMID: 20457564 DOI: 10.1101/cshperspect.a001651]
17. Gabay C. Interleukin-6 and chronic inflammation. Arthritis Res Ther 2006; 8 Suppl 2: S3 [PMID: 16899107 DOI: 10.1186/ar1917]
18. Maihöfner C, Charalambous MP, Bhambra U, Lightfoot T, Geisslinger G, Gooderham NJ. Expression of cyclooxygenase-2 parallels expression of interleukin-1beta, interleukin-6 and NF-kappaB in human colorectal cancer. Carcinogenesis 2003; 24: 665-671 [PMID: 12727794 DOI: 10.1093/carcin/bgg006]
19. Zhao Y, Usatyuk PV, Gorshkova IA, He D, Wang T, Moreno- Vinasco L, Geyh AS, Breysse PN, Samet JM, Spannhake EW, Garcia JG, Natarajan V. Regulation of COX-2 expression and IL-6 release by particulate matter in airway epithelial cells. Am J Respir Cell Mol Biol 2009; 40: 19-30 [PMID: 18617679 DOI: 10.1165/rcmb.2008-0105OC]
20. Harris RE. Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 2009; 17: 55-67 [PMID: 19340409 DOI: 10.1007/s10787-009-8049-8]
21. Wu KK. Cyclooxygenase 2 induction: molecular mechanism and pathophysiologic roles. J Lab Clin Med 1996; 128: 242-245 [PMID: 8783630]
22. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE. Cyclooxygenase in biology and disease. FASEB J 1998; 12: 1063-1073 [PMID: 9737710]
23. Parrett M, Harris R, Joarder F, Ross M, Clausen K, Robertson F. Cyclooxygenase-2 gene expression in human breast cancer. Int J Oncol 1997; 10: 503-507 [PMID: 21533404]
24. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-2 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998; 90: 455-460 [PMID: 9521170 DOI: 10.1093/jnci/90.6.455]
25. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, Koki AT. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000; 89: 2637-2645 [PMID: 11135226 DOI: 10.1002/1097-0142(2000121 5)89]
26. Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62: 632-635 [PMID: 11830510]
27. Costa C, Soares R, Reis-Filho JS, Leitão D, Amendoeira I, Schmitt FC. Cyclo-oxygenase 2 expression is associated with angiogenesis and lymph node metastasis in human breast cancer. J Clin Pathol 2002; 55: 429-434 [PMID: 12037025]
28. Kirkpatrick K, Ogunkolade W, Elkak A, Bustin S, Jenkins P, Ghilchik M, Mokbel K. The mRNA expression of cyclooxygenase-2 (COX-2) and vascular endothelial growth factor (VEGF) in human breast cancer. Curr Med Res Opin 2002; 18: 237-241 [PMID: 12201625 DOI: 10.1185/030079902125000633]
29. Davies G, Salter J, Hills M, Martin LA, Sacks N, Dowsett M. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res 2003; 9: 2651-2656 [PMID: 12855643]
30. Denkert C, Winzer KJ, Müller BM, Weichert W, Pest S, Köbel M, Kristiansen G, Reles A, Siegert A, Guski H, Hauptmann S. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003; 97: 2978-2987 [PMID: 12784332]
31. Shim JY, An HJ, Lee YH, Kim SK, Lee KP, Lee KS. Overexpression of cyclooxygenase-2 is associated with breast carcinoma and its poor prognostic factors. Mod Pathol 2003; 16: 1199-1204 [PMID: 14681319 DOI: 10.1097/01. MP.0000097372.73582.cb]
32. Shim V, Gauthier ML, Sudilovsky D, Mantei K, Chew KL, Moore DH, Cha I, Tlsty TD, Esserman LJ. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res 2003; 63: 2347-2350 [PMID: 12750248]
33. Singh-Ranger G, Kirkpatrick KL, Clark GM, Mokbel K. Cyclo- oxygenase-2 (COX-2) mRNA expression correlates with progesterone receptor positivity in human breast cancer. Curr Med Res Opin 2003; 19: 131-134 [PMID: 12740157 DOI: 10.1080/030079903125001569]
34. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004; 90: 423-429 [PMID: 14735188]
35. Tan KB, Yong WP, Putti TC. Cyclooxygenase-2 expression: a potential prognostic and predictive marker for high-grade ductal carcinoma in situ of the breast. Histopathology 2004; 44: 24-28 [PMID: 14717665 DOI: 10.1111/j.1365-2559.2004.01774.x]
36. Nakopoulou L, Mylona E, Papadaki I, Kapranou A, Giannopoulou I, Markaki S, Keramopoulos A. Overexpression of cyclooxygenase-2 is associated with a favorable prognostic phenotype in breast carcinoma. Pathobiology 2005; 72: 241-249 [PMID: 16374068]
37. Perrone G, Santini D, Vincenzi B, Zagami M, La Cesa A, Bianchi A, Altomare V, Primavera A, Battista C, Vetrani A, Tonini G, Rabitti C. COX-2 expression in DCIS: correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features. Histopathology 2005; 46: 561-568 [PMID: 15842638 DOI: 10.1111/j.1365-2559.2005.02132.x]
38. Takeshita E, Osanai T, Higuchi T, Soumaoro LT, Sugihara K. Elevated cyclooxygenase-2 expression is associated with histological grade in invasive ductal breast carcinoma. J Med Dent Sci 2005; 52: 189-193 [PMID: 16669452]
39. Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. Sur- vivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer 2006; 94: 253-258 [PMID: 16421596]
40. Gunnarsson C, Jansson A, Holmlund B, Ferraud L, Nordenskjöld B, Rutqvist LE, Skoog L, Stål O. Expression of COX-2 and steroid converting enzymes in breast cancer. Oncol Rep 2006; 16: 219-224 [PMID: 16820896]
41. Mehrotra S, Morimiya A, Agarwal B, Konger R, Badve S. Microsomal prostaglandin E2 synthase-1 in breast cancer: a potential target for therapy. J Pathol 2006; 208: 356-363 [PMID: 16353170 DOI: 10.1002/path.1907]
42. Chuah BY, Putti T, Salto-Tellez M, Charlton A, Iau P, Buhari SA, Wong CI, Tan SH, Wong AL, Chan CW, Goh BC, Lee SC. Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant chemotherapy. Ann Oncol 2011; 22: 1748-1754 [PMID: 21355070 DOI: 10.1093/annonc/mdq755]
43. Hartmann LC, Lingle W, Frost MH, Shaun D, Maloney RA, Vierkant V, Pankratz S, Tisty T, Degnim AC, Visscher DW. COX-2 expression in atypia: correlation with breast cancer risk. Proc Amer Assoc Cancer Res 97th Annual Meeting, 2006: Abstract No. 2353
44. Visscher DW, Pankratz VS, Santisteban M, Reynolds C, Ristimäki A, Vierkant RA, Lingle WL, Frost MH, Hartmann LC. Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst 2008; 100: 421-427 [PMID: 18334709 DOI: 10.1093/jnci/djn036]
45. Howe LR, Subbaramaiah K, Brown AM, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocr Relat Cancer 2001; 8: 97-114 [PMID: 11397667 DOI: 10.1677/erc.0.0080097]
46. Karmali RA, Marsh J, Fuchs C. Effect of omega-3 fatty acids on growth of a rat mammary tumor. J Natl Cancer Inst 1984; 73: 457-461 [PMID: 6087007]
47. Karmali RA. Dietary fatty acids, COX-2 blockade, and carcinogenesis. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, Totowa, NJ, 2002: 3-12
48. Joarder F, Abouissa H, Robertson F, Parrett M, Alshafie G, Harris R. Growth arrest of DMBA-induced mammary carcinogenesis with ibuprofen treatment in female Sprague- Dawley rats. Oncol Rep 1997; 4: 1271-1273 [PMID: 21590235]
49. Robertson FM, Parrett ML, Joarder FS, Ross M, Abou-Issa HM, Alshafie G, Harris RE. Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Lett 1998; 122: 165-175 [PMID: 9464506 DOI: 10.1016/s0304-3835(97)00387-x]
50. Abou-Issa HM, Alshafie GA, Harris RE. Chemoprevention of breast cancer by nonsteroidal anti-inflammatory drugs and selective COX-2 blockade in animals. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, Totowa, NJ, 2002: 85-98
51. Harris RE, Alshafie GA, Abou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000; 60: 2101-2103 [PMID: 10786667]
52. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 2001; 276: 18563-18569 [PMID: 11278747 DOI: 10.1074/jbc.M010787200]
53. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989; 299: 1247-1250 [PMID: 2513898]
54. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-1327 [PMID: 8443812]
55. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994; 5: 138-146 [PMID: 8172988]
56. Harris RE, Namboodiri K, Stellman SD, Wynder EL. Breast cancer and NSAID use: heterogeneity of effect in a case-control study. Prev Med 1995; 24: 119-120 [PMID: 7597011 DOI: 10.1006/pmed.1995.1022]
57. Harris R, Namboodiri K, Farrar W. Epidemiologic-study of nonsteroidal antiinflammatory drugs and breast-cancer. Oncol Rep 1995; 2: 591-592 [PMID: 21597781]
58. Rosenberg L. Nonsteroidal anti-inflammatory drugs and cancer. Prev Med 1995; 24: 107-109 [PMID: 7597007 DOI: 10.1006/pmed.1995.1018]
59. Harris RE, Namboodiri KK, Farrar WB. Nonsteroidal antiinflammatory drugs and breast cancer. Epidemiology 1996; 7: 203-205 [PMID: 8834563]
60. Egan KM, Stampfer MJ, Giovannucci E, Rosner BA, Colditz GA. Prospective study of regular aspirin use and the risk of breast cancer. J Natl Cancer Inst 1996; 88: 988-993 [PMID: 8667430 DOI: 10.1093/jnci/88.14.988]
61. Harris RE, Kasbari S, Farrar WB. Prospective study of nonsteroidal anti-inflammatory drugs and breast cancer. Oncol Rep 1999; 6: 71-73 [PMID: 9864404]
62. Johnson TJ, Anderson KI, Lazovich D, Folsom AR. Association of aspirin and other nonsteroidal anti-inflammatory drug use with incidence of postmenopausal breast cancer. Proc Amer Assoc Cancer Res 2001; 42: Abstract 4098: 763
63. Neugut AI, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, Rahman MI, Khan ZR, Chen L, Pablos-Mendez A, Shea S. Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev 1998; 7: 869-873 [PMID: 9796631]
64. Coogan PF, Rao SR, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Stolley PD, Shapiro S. The relationship of nonsteroidal anti-inflammatory drug use to the risk of breast cancer. Prev Med 1999; 29: 72-76 [PMID: 10446030 DOI: 10.1006/pmed.1999.0518]
65. Sharpe CR, Collet JP, McNutt M, Belzile E, Boivin JF, Hanley JA. Nested case-control study of the effects of non-steroidal anti-inflammatory drugs on breast cancer risk and stage. Br J Cancer 2000; 83: 112-120 [PMID: 10883678 DOI: 10.1054/bjoc.2000.1119]
66. Cotterchio M, Kreiger N, Sloan M, Steingart A. Nonsteroidal anti-inflammatory drug use and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10: 1213-1217 [PMID: 11700271]
67. Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ 2000; 320: 1642-1646 [PMID: 10856067 DOI: 10.1136/bmj.320.7250.1642]
68. Meier CR, Schmitz S, Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancer. Pharmacotherapy 2002; 22: 303-309 [PMID: 11898889 DOI: 10.1592/phco.22.5.303.33189]
69. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003; 63: 6096-6101 [PMID: 14522941]
70. Moorman PG, Grubber JM, Millikan RC, Newman B. Association between non-steroidal anti-inflammatory drugs (NSAIDs) and invasive breast cancer and carcinoma in situ of the breast. Cancer Causes Control 2003; 14: 915-922 [PMID: 14750530 DOI: 10.1023/B:caco.0000007973.59863.66]
71. Garcia Rodriguez LA, Gonzalez-Perez AG. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Brit J Cancer 2004; 91: 535-539 [DOI: 10.1038/sj. bjc.6602003]
72. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, Subbaramaiah K, Dannenberg AJ, Neugut AI. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA 2004; 291: 2433-2440 [PMID: 15161893 DOI: 10.1001/jama. 291.20.2 433]
73. Swede H, Mirand AL, Menezes RJ, Moysich KB. Association of regular aspirin use and breast cancer risk. Oncology 2005; 68: 40-47 [PMID: 15802928 DOI: 10.1159/000084818]
74. Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294: 47-55 [PMID: 15998890 DOI: 10.1001/jama.294.1.47]
75. Rahme E, Ghosn J, Dasgupta K, Rajan R, Hudson M. Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer. BMC Cancer 2005; 5: 159 [PMID: 16343343 DOI: 10.1186/1471-2407-5-159]
76. Jacobs EJ, Thun MJ, Connell CJ, Rodriguez C, Henley SJ, Feigelson HS, Patel AV, Flanders WD, Calle EE. Aspirin and other nonsteroidal anti-inflammatory drugs and breast cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2005; 14: 261-264 [PMID: 15668504]
77. Marshall SF, Bernstein L, Anton-Culver H, Deapen D, Horn- Ross PL, Mohrenweiser H, Peel D, Pinder R, Purdie DM, Reynolds P, Stram D, West D, Wright WE, Ziogas A, Ross RK. Nonsteroidal anti-inflammatory drug use and breast cancer risk by stage and hormone receptor status. J Natl Cancer Inst 2005; 97: 805-812 [PMID: 15928301 DOI: 10.1093/jnci/dji140]
78. Zhang Y, Coogan PF, Palmer JR, Strom BL, Rosenberg L. Use of nonsteroidal antiinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited. Am J Epidemiol 2005; 162: 165-170 [PMID: 15972932 DOI: 10.1093/aje/kwi182]
79. Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006; 6: 27 [PMID: 16445867 DOI: 10.1186/1471-2407-6-27]
80. Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM. Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res 2006; 8: R71 [PMID: 17181859 DOI: 10.1186/bcr1629]
81. Slattery ML, Curtin K, Baumgartner R, Sweeney C, Byers T, Giuliano AR, Baumgartner KB, Wolff RR. IL6, aspirin, nonsteroidal anti-inflammatory drugs, and breast cancer risk in women living in the southwestern United States. Cancer Epidemiol Biomarkers Prev 2007; 16: 747-755 [PMID: 17416766 DOI: 10.1158/1055-9965.epi-06-0667]
82. Kirsh VA, Kreiger N, Cotterchio M, Sloan M, Theis B. Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol 2007; 166: 709-716 [PMID: 17660454 DOI: 10.1093/aje/kwm216]
83. Gallicchio L, McSorley MA, Newschaffer CJ, Thuita LW, Huang HY, Hoffman SC, Helzlsouer KJ. Nonsteroidal antiinflammatory drugs, cyclooxygenase polymorphisms, and the risk of developing breast carcinoma among women with benign breast disease. Cancer 2006; 106: 1443-1452 [PMID: 16502408 DOI: 10.1002/cncr.21763]
84. Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN. Nonsteroidal antiinflammatory drugs and breast cancer risk: the multiethnic cohort. Am J Epidemiol 2007; 166: 1150-1158 [PMID: 17698973 DOI: 10.1093/aje/kwm195]
85. Ready A, Velicer CM, McTiernan A, White E. NSAID use and breast cancer risk in the VITAL cohort. Breast Cancer Res Treat 2008; 109: 533-543 [PMID: 17674199 DOI: 10.1007/s10549-007-9665-x]
86. Gierach GL, Lacey JV, Schatzkin A, Leitzmann MF, Richesson D, Hollenbeck AR, Brinton LA. Nonsteroidal antiinflammatory drugs and breast cancer risk in the National Institutes of Health-AARP Diet and Health Study. Breast Cancer Res 2008; 10: R38 [PMID: 18447943 DOI: 10.1186/bcr2089]
87. Friis S, Thomassen L, Sørensen HT, Tjønneland A, Overvad K, Cronin-Fenton DP, Vogel U, McLaughlin JK, Blot WJ, Olsen JH. Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev 2008; 17: 88-96 [PMID: 18287865 DOI: 10.1097/CEJ.0b013e3282b6fd55]
88. Brasky TM, Bonner MR, Moysich KB, Ambrosone CB, Nie J, Tao MH, Edge SB, Kallakury BV, Marian C, Goerlitz DS, Trevisan M, Shields PG, Freudenheim JL. Non-steroidal antiinflammatory drugs (NSAIDs) and breast cancer risk: differences by molecular subtype. Cancer Causes Control 2011; 22: 965-975 [PMID: 21516318 DOI: 10.1007/s10552-011-9769-9]
89. Bosco JL, Palmer JR, Boggs DA, Hatch EE, Rosenberg L. Regular aspirin use and breast cancer risk in US Black women. Cancer Causes Control 2011; 22: 1553-1561 [PMID: 21877122 DOI: 10.1007/s10552-011-9832-6]
90. Bardia A, Olson JE, Vachon CM, Lazovich D, Vierkant RA, Wang AH, Limburg PJ, Anderson KE, Cerhan JR. Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat 2011; 126: 149-155 [PMID: 20669045 DOI: 10.1007/s10549-010-1074-x]
91. Zhang X, Smith-Warner SA, Collins LC, Rosner B, Willett WC, Hankinson SE. Use of aspirin, other nonsteroidal anti-inflammatory drugs, and acetaminophen and postmenopausal breast cancer incidence. J Clin Oncol 2012; 30: 3468-3477 [PMID: 22927520 DOI: 10.1200/jco.2012.42.2006]
92. Schlesselman JJ. Case Control Studies. New York: Oxford University Press, 1982
93. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30 [PMID: 3678409]
94. González-Pérez A, García Rodríguez LA, López-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a metaanalysis. BMC Cancer 2003; 3: 28 [PMID: 14588079 DOI: 10.1186/1471-2407-3-28]
95. Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005; 13: 559-583 [PMID: 15756426]
96. Nelson JE, Harris RE. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000; 7: 169-170 [PMID: 10601612]
97. Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 2002; 9: 693-695 [PMID: 12066194]
98. Harris RE, Beebe-Donk J, Alshafie GA. Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. Int J Biol Sci 2007; 3: 328-334 [PMID: 17589567]
99. Harris RE, Beebe-Donk J, Alshafie GA. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2008; 8 4. [PMID: 18702823 DOI: 10.1186/1471-2407-8-237]
100. Harris RE, Beebe-Donk J, Alshafie GA. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell Biochem 2007; 42: 193-212 [PMID: 17612052]
101. Harris RE, Beebe J, Alshafie GA. Reduction in cancer risk by selective and non-selective cyclooxygenase 2 (COX-2) inhibitors. J Exp Pharm 2012; 4: 91-96 [DOI: 10.2147/jep.S23826]
102. Kwan ML, Habel LA, Slattery ML, Caan B. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 2007; 18: 613-620 [PMID: 17404892 DOI: 10.1007/s10552-007-9003-y]
103. Blair CK, Sweeney C, Anderson KE, Folsom AR. NSAID use and survival after breast cancer diagnosis in post-menopaus- al women. Breast Cancer Res Treat 2007; 101: 191-197 [PMID: 16823508 DOI: 10.1007/s10549-006-9277-x]
104. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol 2010; 28: 1467-1472 [PMID: 20159825 DOI: 10.1200/jco.2009.22.7918]
105. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144: 2195-2200 [PMID: 12746274 DOI: 10.1210/EN.2003-0285]
106. Nickell WB, Skelton J. Breast fat and fallacies: more than 2 years of anatomical fantasy. J Hum Lact 2005; 21: 126-130 [PMID: 15886338 DOI: 10.1177/0890334405276471]
107. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013
108. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, Kopelovich L, Hudis CA, Dannenberg AJ. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012; 2: 356-365 [PMID: 22576212 DOI: 10.1158/2159-8290.cd-11-0241]
109. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, Zhou XK, Blaho VA, Hla T, Yang P, Kopelovich L, Hudis CA, Dannenberg AJ. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 2011; 4: 329-346 [PMID: 21372033 DOI: 10.1158/1940-6207.capr-10-0381]
110. Simpson ER, Brown KA. Minireview: Obesity and breast cancer: a tale of inflammation and dysregulated metabolism. Mol Endocrinol 2013; 27: 715-725 [PMID: 23518927 DOI: 10.1210/ME.2013-1011]
111. Rose DP, Vona-Davis L. Biochemical and molecular mechanisms for the association between obesity, chronic inflammation, and breast cancer. Biofactors 2014; 40: 1-12 [PMID: 23857944 DOI: 10.1002/biof.1109]
112. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996; 137: 5739-5742 [PMID: 8940410 DOI: 10.1210/endo.137.12.8940410]
113. Harris RE, Robertson FM, Abou-Issa HM, Farrar WB, Brueggemeier R. Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer. Med Hypotheses 1999; 52: 291-292 [PMID: 10465664 DOI: 10.1054/mehy. 1998.0009]
114. Shiff SJ, Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 1999; 190: 445-450 [PMID: 10449515]
115. Subbaramaiah K, Dannenberg AJ. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 2003; 24: 96-102 [PMID: 12559775 DOI: 10.1016/S0165-6147(02)00043-3]
116. Karmali RA, Marsh J. Antitumor activity in a rat mammary adenocarcinoma: the effect of cyclooxygenase inhibitors and immunization against prostaglandin E2. Prostaglandins Leukot Med 1985; 20: 283-286 [PMID: 3937158]
117. Rose DP, Connolly JM. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 1999; 83: 217-244 [PMID: 10576293 DOI: 10.1016/s0163-7258(99)00026-1]
118. Cakir Y, Plummer HK, Tithof PK, Schuller HM. Beta-adrenergic and arachidonic acid-mediated growth regulation of human breast cancer cell lines. Int J Oncol 2002; 21: 153-157 [PMID: 12063562]
119. Chow LW, Zhu L, Loo WT, Lui EL. Aberrant methylation of cyclooxygenase-2 in breast cancer patients. Biomed Pharmacother 2005; 59 Suppl 2: S264-S267 [PMID: 16507389 DOI: 10.1016/s0753-3322(05)80042-3]
120. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Lett 1999; 140: 27-35 [PMID: 10403538]
121. Richards JA, Brueggemeier RW. Interactions of cyclooxygenase and aromatase pathways in normal and malignant breast cells. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, Totowa, NJ, 2002: 205-224
122. Díaz-Cruz ES, Brueggemeier RW. Interrelationships between cyclooxygenases and aromatase: unraveling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med Chem 2006; 6: 221-232 [PMID: 16712450 DOI: 10.2174/187152006776930873]
123. Weinberg OK, Marquez-Garban DC, Fishbein MC, Goodglick L, Garban HJ, Dubinett SM, Pietras RJ. Aromatase inhibitors in human lung cancer therapy. Cancer Res 2005; 65: 11287-11291 [PMID: 16357134 DOI: 10.1158/0008-5472. can-05-2737]
124. Fiorelli G, Picariello L, Martineti V, Tonelli F, Brandi ML. Estrogen synthesis in human colon cancer epithelial cells. J Steroid Biochem Mol Biol 1999; 71: 223-230 [PMID: 10704911 DOI: 10.1016/s0960-0760(99)00144-2]
125. Ellem SJ, Risbridger GP. Aromatase and prostate cancer. Minerva Endocrinol 2006; 31: 1-12 [PMID: 16498360]
126. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002; 8: 289-293 [PMID: 11875501 DOI: 10.1038/nm0302-289]
127. Coffey RJ, Hawkey CJ, Damstrup L, Graves-Deal R, Daniel VC, Dempsey PJ, Chinery R, Kirkland SC, DuBois RN, Jetton TL, Morrow JD. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells. Proc Natl Acad Sci USA 1997; 94: 657-662 [PMID: 9012840]
128. Mestre JR, Subbaramaiah K, Sacks PG, Schantz SP, Tanabe T, Inoue H, Dannenberg AJ. Retinoids suppress epidermal growth factor-induced transcription of cyclooxygenase-2 in human oral squamous carcinoma cells. Cancer Res 1997; 57: 2890-2895 [PMID: 9230197]
129. Kinoshita T, Takahashi Y, Sakashita T, Inoue H, Tanabe T, Yoshimoto T. Growth stimulation and induction of epidermal growth factor receptor by overexpression of cyclooxygenases 1 and 2 in human colon carcinoma cells. Biochim Biophys Acta 1999; 1438: 120-130 [PMID: 10216286 DOI: 10.1016/S1388-1981(99)00034-7]
130. Moraitis D, Du B, De Lorenzo MS, Boyle JO, Weksler BB, Cohen EG, Carew JF, Altorki NK, Kopelovich L, Subbaramaiah K, Dannenberg AJ. Levels of cyclooxygenase-2 are increased in the oral mucosa of smokers: evidence for the role of epidermal growth factor receptor and its ligands. Cancer Res 2005; 65: 664-670 [PMID: 15695412]
131. Dannenberg AJ, Lippman SM, Mann JR, Subbaramaiah K, DuBois RN. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23: 254-266 [PMID: 15637389]
132. Bhattacharjee RN, Timoshenko AV, Cai J, Lala PK. Relationship between cyclooxygenase-2 and human epidermal growth factor receptor 2 in vascular endothelial growth factor C up-regulation and lymphangiogenesis in human breast cancer. Cancer Sci 2010; 101: 2026-2032 [PMID: 20608938 DOI: 10.1111/j.1349-7006.2010.01647.x]
133. Whelan J, McEntee MF. Nonsteroidal anti-inflammatory drugs, prostaglandins, and APC-driven intestinal tumorigenesis. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, Totowa, NJ, 2002: 117-145
134. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev 1999; 9: 15-21 [PMID: 10072352]
135. Henderson BR. Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover. Nat Cell Biol 2000; 2: 653-660 [PMID: 10980707 DOI: 10.1038/35023605]
136. Clevers H. Colon cancer-understanding how NSAIDs work. N Engl J Med 2006; 354: 761-763 [PMID: 16481647 DOI: 10.1056/nejmcibr055457]
137. Castellone MD, Teramoto H, Williams BO, Druey KM, Gutkind JS. Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science 2005; 310: 1504-1510 [PMID: 16293724 DOI: 10.1126/science.1116221]
138. He TC. Association of COX-2 and PPARs in carcinogenesis and chemoprevention. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, Totowa, NJ, 2002: 225-244
139. Bocca C, Ievolella M, Autelli R, Motta M, Mosso L, Torchio B, Bozzo F, Cannito S, Paternostro C, Colombatto S, Parola M, Miglietta A. Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness. Expert Opin Ther Targets 2014; 18: 121-135 [PMID: 24325753 DOI: 10.1517/14728222.2014.86 0447]
140. Liehr JG. Hormone-associated cancer: mechanistic similarities between human breast cancer and estrogen-induced kidney carcinogenesis in hamsters. Environ Health Perspect 1997; 4 Suppl 3: 565-569 [PMID: 9167996]
141. Yager JD. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr 2000; (27): 67-73 [PMID: 10963620]
142. Cavalieri EL, Rogan EG, Chakravarti D. Initiation of cancer and other diseases by catechol ortho-quinones: a unifying mechanism. Cell Mol Life Sci 2002; 59: 665-681 [PMID: 12022473]
143. Yue W, Santen RJ, Wang JP, Li Y, Verderame MF, Bocchinfuso WP, Korach KS, Devanesan P, Todorovic R, Rogan EG, Cavalieri EL. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 2003; 86: 477-486 [PMID: 14623547 DOI: 10.1016/S0960-0760(03)00377-7]
144. Rogan EG, Badawi AF, Devanesan PD, Meza JL, Edney JA, West WW, Higginbotham SM, Cavalieri EL. Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 2003; 24: 697-702 [PMID: 12727798 DOI: 10.1093/carcin/bgg004]
145. Hurh YJ, Chen ZH, Na HK, Han SY, Surh YJ. 2-Hydroxyestradiol induces oxidative DNA damage and apoptosis in human mammary epithelial cells. J Toxicol Environ Health A 2004; 67: 1939-1953 [PMID: 15513894 DOI: 10.1080/152873904 90514598]
146. Xue W, Warshawsky D. Metabolic activation of polycyclic and heterocyclic aromatic hydrocarbons and DNA damage: a review. Toxicol Appl Pharmacol 2005; 206: 73-93 [PMID: 15963346 DOI: 10.1016/j.taap.2004.11.006]
147. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006; 354: 270-282 [PMID: 16421368 DOI: 10.1056/nejmra050776]
148. Marnett LJ. Lipid peroxidation-DNA damage by malondialdehyde. Mutat Res 1999; 424: 83-95 [PMID: 10064852 DOI: 10.1016/s0027-5107(99)00010-x]
149. Plastaras JP, Guengerich FP, Nebert DW, Marnett LJ. Xenobiotic- metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde. J Biol Chem 2000; 275: 11784-11790 [PMID: 10766802 DOI: 10.1074/jbc.275.16.11784]
150. Marnett LJ, Basu AK, O'Hara SM, Weller PE, Rahman AFMM, Oliver JP. Reaction of malondialdehyde with guanine nucleosides: formation of adducts containing oxadrazabicyclononene residues in the base-pairing region. J Am Chem Soc 1986; 108: 1348-1350[DOI: 10.1021/ja00266a065]
151. Sharma RA, Gescher A, Plastaras JP, Leuratti C, Singh R, Gallacher-Horley B, Offord E, Marnett LJ, Steward WP, Plummer SM. Cyclooxygenase-2, malondialdehyde and pyrimidopurinone adducts of deoxyguanosine in human colon cells. Carcinogenesis 2001; 22: 1557-1560 [PMID: 11532880 DOI: 10.1093/carcin/22.9.1557]
152. Folkman J. Angiogenesis. Annu Rev Med 2006; 57: 1-18 [PMID: 16409133 DOI: 10.1146/annurev.med.57.121304.131306]
153. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 2000; 60: 1306-1311 [PMID: 10728691]
154. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 2007; 26: 525-534 [PMID: 17763971 DOI: 10.1007/s10555-007-9096-5]
155. Timoshenko AV, Chakraborty C, Wagner GF, Lala PK. COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. Br J Cancer 2006; 94: 1154-1163 [PMID: 16570043 DOI: 10.1038/sj.bjc.6603067]
156. Zhang XH, Huang DP, Guo GL, Chen GR, Zhang HX, Wan L, Chen SY. Coexpression of VEGF-C and COX-2 and its association with lymphangiogenesis in human breast cancer. BMC Cancer 2008; 8: 4 [PMID: 18190720 DOI: 10.1186/1471-2407-8-4]
157. Yoshinaka R, Shibata MA, Morimoto J, Tanigawa N, Otsuki Y. COX-2 inhibitor celecoxib suppresses tumor growth and lung metastasis of a murine mammary cancer. Anticancer Res 2006; 26: 4245-4254 [PMID: 17201140]
158. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501 [PMID: 8521479 DOI: 10.1016/0092-8674(95)90127-2]
159. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2004; 2: 632-642 [PMID: 15561779]
160. Sugimoto T, Bartholomeusz C, Tari AM, Ueno NT. Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells. Breast Cancer Res 2007; 9: R41 [PMID: 17612393 DOI: 10.1186/bcr1739]
161. Totzke G, Schulze-Osthoff K, Jänicke RU. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene 2003; 22: 8021-8030 [PMID: 12970750 DOI: 10.1038/sj.onc.1206837]
162. Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res 2000; 6: 2513-2520 [PMID: 10873107]
163. Burd R, Choy H, Dicker A. Potential for inhibitors of cyclooxygenase-2 to enhance tumor radioresponse. In: RE Harris, ed. COX-2 Blockade in Cancer Prevention and Therapy. Humana Press, Totowa, NJ, 2002: 301-311
164. Subbaramaiah K, Chung WJ, Dannenberg AJ. Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. J Biol Chem 1998; 273: 32943-32949 [PMID: 9830045 DOI: 10.1074/jbc.273.49.32943]
165. Levitt RJ, Buckley J, Blouin MJ, Schaub B, Triche TJ, Pollak M. Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochem Biophys Res Commun 2004; 316: 421-428 [PMID: 15020235 DOI: 10.1016/j. bbrc.2004.02.062]
166. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer: evidence for involvement of AP-1 and PEA3. J Biol Chem 2002; 277: 18649-18657 [PMID: 11901151 DOI: 10.1074/jbc.M111415200]
167. Benoit V, Relic B, Leval Xd Xd, Chariot A, Merville MP, Bours V. Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene 2004; 23: 1631-1635 [PMID: 14985703 DOI: 10.1038/sj.onc.1207295]
168. Sivula A, Talvensaari-Mattila A, Lundin J, Joensuu H, Haglund C, Ristimäki A, Turpeenniemi-Hujanen T. Association of cyclooxygenase-2 and matrix metalloproteinase-2 expression in human breast cancer. Breast Cancer Res Treat 2005; 89: 215-220 [PMID: 15754118 DOI: 10.1007/s10549-004-0714-4]
169. Larkins TL, Nowell M, Singh S, Sanford GL. Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase expression. BMC Cancer 2006; 6: 181 [PMID: 16831226 DOI: 10.1186/1471-2407-6-181]
170. Kang JH, Song KH, Jeong KC, Kim S, Choi C, Lee CH, Oh SH. Involvement of Cox-2 in the metastatic potential of chemotherapy- resistant breast cancer cells. BMC Cancer 2011; 11: 8. [PMID: 21813027 DOI: 10.1186/1471-2407-11-334]
171. Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A. COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol 2005; 26: 1393-1399 [PMID: 15809733]
172. Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. Induction of antigen- specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 1998; 95: 1178-1183 [PMID: 9448305]
173. Pockaj BA, Basu GD, Pathangey LB, Gray RJ, Hernandez JL, Gendler SJ, Mukherjee P. Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer. Ann Surg Oncol 2004; 11: 328-339 [PMID: 14993030]
174. Hecht SS. Tobacco smoke carcinogens and breast cancer. Environ Mol Mutagen 2002; 39: 119-126 [PMID: 11921179 DOI: 10.1002/em.10071]
175. Salaspuro M. Acetaldehyde as a common denominator and cumulative carcinogen in digestive tract cancers. Scand J Gastroenterol 2009; 44: 912-925 [PMID: 19396661 DOI: 10.1080/00 365520902912563]
176. McGettigan P, Henry D. Cardiovascular risk with nonsteroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; 8: e1001098 [PMID: 21980265 DOI: 10.1371/journal. pmed.1001098]